Skip to main content

alk inhibitor nvl-655

Generic: ALK Inhibitor NVL-655

alk inhibitor nvl-655: 3 clinical trials tracked.

alk inhibitor nvl-655 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about alk inhibitor nvl-655, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trial Registry Records (3)

Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

NCT06834074Registry updated 2026-09-21·NUVL
Available
Expanded Access50 sites · Australia, Canada, France, Italy…Nuvalent Inc.

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

NCT06765109Registry updated 2026-09-30·Phase 3·NUVL
Recruiting

Primary endpoint: Progression-free survival (PFS) per blinded independent central review (BICR)

InterventionalRandomizedsingle450 targetStarted 2025-07Completion 2029-12159 sites · Argentina, Australia, Austria, Belgium…Nuvalent Inc.

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

NCT05384626Registry updated 2026-05-27·Phase 1/Phase 2·NUVL
Recruiting

Primary endpoint: Dose limiting toxicities (DLTs) (Phase 1)

Interventionalopen840 targetStarted 2022-06Completion 2028-0150 sites · Australia, Belgium, Canada, France…Nuvalent Inc.